The stock now trades in line with diversified peers, the analyst said. "With the deal not yet closed, we don't expect SUN to be able to demonstrate success here for the next several quarters," Doubles said. — Pia Singh 5:38 a.m.: Berenberg hikes Eli Lilly price target Eli Lilly has been on a tear this year, and Berenberg expects even more gains from here. Analyst Kerry Holford reiterated his buy rating on the stock and raised his price target to $850 from $680. The new forecast implies upside of 10% from Monday's close. Holford cited prescription trends around the company's weight loss drug Zepbound for the target increase. "Early prescription trends for Zepbound in obesity are encouraging," the analyst said. "Our discussions with obesity experts confirm that patient demand for drug therapy remains high and support an appreciation of Zepbound's superior clinical profile.